259 results on '"Ferreira González I"'
Search Results
2. Cardiac complications during pregnancy are better predicted with the modified WHO risk score
- Author
-
Pijuan-Domènech, A., Galian, L., Goya, M., Casellas, M., Merced, C., Ferreira-Gonzalez, I., Marsal-Mora, J.R., Dos-Subirà, L., Subirana-Domènech, M.T., Pedrosa, V., Baró-Marine, F., Manrique, S., Casaldàliga-Ferrer, J., Tornos, P., Cabero, L., and Garcia-Dorado, D.
- Published
- 2015
- Full Text
- View/download PDF
3. (407) - Screening of Advanced Heart Failure Features Among Patients with LVEF
- Author
-
Ródenas-Alesina, E., Olivella, A., Soriano-Colome, T., Fernandez, A. Mendez, Uribarri, A., and Ferreira-González, I.
- Published
- 2024
- Full Text
- View/download PDF
4. Problems with Use of Composite End Points in Cardiovascular Trials: Systematic Review of Randomised Controlled Trials
- Author
-
Ferreira-González, I., Busse, J. W., Heels-Ansdell, D., Montori, V. M., Akl, E. A., Bryant, D. M., Alonso, J., Jaeschke, R., Schünemann, H. J., Permanyer-Miralda, G., Domingo-Salvany, A., and Guyatt, G. H.
- Published
- 2007
- Full Text
- View/download PDF
5. Geometric, Biomechanic and Haemodynamic Aortic Abnormalities Assessed by 4D Flow Cardiovascular Magnetic Resonance in Patients Treated by TEVAR Following Blunt Traumatic Thoracic Aortic Injury
- Author
-
Gil-Sala, D., primary, Guala, A., additional, Garcia Reyes, M.E., additional, Azancot, M.A., additional, Dux-Santoy, L., additional, Allegue Allegue, N., additional, Teixido Turà, G., additional, Goncalves Martins, G., additional, Ruiz Muñoz, A., additional, Constenla García, I., additional, Evangelista, A., additional, Tello Díaz, C., additional, Ferreira González, I., additional, Rodríguez-Palomares, J.F., additional, and Bellmunt, S., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Planning and reporting of quality-of-life outcomes in cancer trials
- Author
-
Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blümle, A., Tomonaga, Y., Amstutz, A., Briel, M., Kasenda, B., Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blümle, A., Tomonaga, Y., Saccilotto, R., Amstutz, A., Bengough, T., Meerpohl, J. J., Stegert, M., Olu, K. K., Tikkinen, K. A. O., Neumann, I., Carrasco-Labra, A., Faulhaber, M., Mulla, S. M., Mertz, D., Akl, E. A., Sun, X., Bassler, D., Busse, J. W., Ferreira-González, I., Lamontagne, F., Nordmann, A., Gloy, V., Raatz, H., Moja, L., Rosenthal, R., Ebrahim, S., Vandvik, P. O., Johnston, B. C., Walter, M. A., Burnand, B., Schwenkglenks, M., Hemkens, L. G., Bucher, H. C., Guyatt, G. H., Briel, M., and Kasenda, B.
- Published
- 2015
- Full Text
- View/download PDF
7. Prospective registry of symptomatic severe aortic stenosis in octogenarians: a need for intervention
- Author
-
Martínez-Sellés, M., Doblas, Gómez J. J., Hevia, Carro A., de la Villa, García B., Ferreira-González, I., Tello, Alonso A., Ogando, Andión R., Vera, Ripoll T., Jiménez, Arribas A., Carrillo, P., Pascual, Rodríguez C., i Romeva, Casares M., Borras, X., Cornide, L., and López-Palop, R.
- Published
- 2014
- Full Text
- View/download PDF
8. Impact of implementing a dyslipidemia management guideline on cholesterol control for secondary prevention of ischemic heart disease in primary care
- Author
-
Universitat Rovira i Virgili, Drago EF; Llorca MRD; Martín CA; Ferreira-González I; Rojas ZH; Gonçalves AQ; López-Pablo C, Universitat Rovira i Virgili, and Drago EF; Llorca MRD; Martín CA; Ferreira-González I; Rojas ZH; Gonçalves AQ; López-Pablo C
- Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Cardiovascular diseases (CVD) are the main cause of death worldwide. The control of CVD risk factors, such as dyslipidemia, reduces their mortality rate. Nonetheless, fewer than 50% of patients with ischemic heart disease (IHD) have good cholesterol control. Our objective is to assess whether the level of participation of general practitioners (GPs) in activities to implement a dyslipidemia management guideline, and the characteristics of the patient and physician are associated with cholesterol control in IHD patients. We undertook a quasi-experimental, uncontrolled, before-and-after study of 1151 patients. The intervention was carried out during 2010 and 2011, and consisted of a face-to-face training and online course phase (Phase 1), and another of face-to-face feedback (Phase 2). The main outcome variable was the low-density lipoprotein cholesterol (LDL-C) control, whereby values of <100 mg/dL (2.6 mmol/L) were set as a good level of control, according to the recommendations of the guidelines in force in 2009. After Phase 1, 6.7% more patients demonstrated good cholesterol control. With respect to patient characteristics, being female and being older were found to be risk factors of poor control. Being diabetic and having suffered a stroke were protective factors. Of the GPs’ characteristics, being tutor in a teaching center for GP residents and having completed the online course were found to be protective factors. We concluded that cholesterol control in IHD patients was influenced by the type of training activity undertook by physicians during the implementation of the GPC, and patient and physician characteristics. We highlight that if we apply the recent targets of the European guideline, which establish
- Published
- 2020
9. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study
- Author
-
Sambola, A, Ferreira-González, I, Angel, J, Alfonso, F, Maristany, J, Rodríguez, O, Bueno, H, López-Minguez, J R, Zueco, J, Fernández-Avilés, F, Román, A San, Prendergast, B, Mainar, V, García-Dorado, D, and Tornos, P
- Published
- 2009
- Full Text
- View/download PDF
10. Enoxaparin as bridging anticoagulant treatment in cardiac surgery
- Author
-
Rivas-Gándara, N, Ferreira-González, I, Tornos, P, Torrents, A, Permanyer-Miralda, G, Nicolau, I, Arellano-Rodrigo, E, Vallejo, N, Igual, A, and Soler-Soler, J
- Published
- 2008
- Full Text
- View/download PDF
11. Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
- Author
-
Avanzas P, Valencia F, Ballesteros S, Ruiz-Nodar JM, Ferreiro JL, Tello Montoliu A, Pérez de Prado A, Romero Moreno M, Bravo MS, Ruiz Ortiz M, Escobar C, Roldán I, Vivas Balcones D, San Román A, Alfonso F, Evangelista A, Ferreira-González I, Jiménez Navarro M, Marín F, Pérez de Isla L, Rodríguez Padial L, Sánchez Fernández PL, Sionis A, Vázquez García R, SEC Working Group for the 2017 ESC Focused Update on Dual Antiplatelet Therapy i, Expert Reviewers for the 2017 ESC Focused Update on Dual Antiplatelet Therapy in, and SEC Guidelines Committee
- Published
- 2018
12. 'A pragmatic approach for mortality prediction after surgery in infective endocarditis' – Author's reply
- Author
-
Ferreira-González, I., primary, Fernández-Hidalgo, N., additional, and Ribera, A., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Correction to: Planning and reporting of quality-of-life outcomes in cancer trials
- Author
-
Schandelmaier, S., primary, Conen, K., additional, von Elm, E., additional, You, J.J., additional, Blümle, A., additional, Tomonaga, Y., additional, Saccilotto, R., additional, Amstutz, A., additional, Bengough, T., additional, Meerpohl, J.J., additional, Stegert, M., additional, Olu, K.K., additional, Tikkinen, K.A.O., additional, Neumann, I., additional, Carrasco-Labra, A., additional, Faulhaber, M., additional, Mulla, S.M., additional, Mertz, D., additional, Akl, E.A., additional, Sun, X., additional, Bassler, D., additional, Busse, J.W., additional, Ferreira-González, I., additional, Lamontagne, F., additional, Nordmann, A., additional, Gloy, V., additional, Raatz, H., additional, Moja, L., additional, Rosenthal, R., additional, Ebrahim, S., additional, Vandvik, P.O., additional, Johnston, B.C., additional, Walter, M.A., additional, Burnand, B., additional, Schwenkglenks, M., additional, Hemkens, L.G., additional, Bucher, H.C., additional, Guyatt, G.H., additional, Briel, M., additional, and Kasenda, B., additional
- Published
- 2016
- Full Text
- View/download PDF
14. Prospective registry of symptomatic severe aortic stenosis in octogenarians: a need for intervention
- Author
-
Martínez Sellés Oliveria Soares, Manuel, Gómez Doblas, J. J., Hevia Carro, A., García de la Villa, Bernardo, Ferreira-González, I., Tello Alonso, A., Ogando Andión, R., Vera Ripoll, T., Jiménez Arribas, A., Carrillo, P., Rodríguez Pascual, Carlos, Romeva Casares, M., Borras, X., Cornide, L., López Palop, Ramón, The PEGASO Registry Group, PEGASO Registry Group, [Martínez-Sellés,M] Servicio de Cardiología, Hospital General Universitario Gregorio Marañón. Universidad Europea de Madrid, Madrid, Spain. [Gómez Doblas,JJ] Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. [Carro Hevia,A] Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain. [García de la Villa,B] Servicio de Cardiología, Hospital de Manacor, Mallorca, Spain. [Ferreira-González,I] Unidad de Epidemiología del Servicio de Cardiología, Hospital Vall d'Hebron, CIBER de Epidemiología y Salud Pública (CIBERESP) y Universitat Autónoma de Barcelona, Spain. [Alonso Tello,A] Servicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain. [Andión Ogando,R] Servicio de Cardiología, Hospital Clínico Universitario, Valladolid, Spain. [Ripoll Vera,T] Servicio de Cardiología, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain. [Arribas Jiménez,A] Servicio de Cardiología, Hospital Clínico Universitario, Salamanca, Spain. [Carrillo,P, López-Palop,R] Servicio de Cardiología, Hospital Universitario San Juan, San Juan de Alicante, Spain. [Rodríguez Pascual] Servicio de Geriatría, Complejo Hospitalario Universitario do Meixoeiro, Vigo, Spain. [Casares i Romeva,M] Servicio de Cardiología, Hospital Plató, Barcelona, Spain. [Borras,X] Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Cornide,L] Servicio de Medicina Interna, Hospital del Sureste, Arganda del Rey, Spain., and This work was supported by funds from the NCI Breast SPORE program Grant No. P50-CA58223-09A1 (CMP), by RO1-CA138255 (CMP), by the Breast Cancer Research Foundation (CMP and MJE), National Cancer Institute (NCI) Strategic Partnering to Evaluate Cancer Signatures Grant No. U01 CA114722-01 (MJE), by the Sociedad Española de Oncología Médica (AP), by FEDER (RETICC-RD12/0036/0051, RD12/0036/0042, RD12/0036/0076, RD12/0036/0070), by Instituto de Salud Carlos III—PI13/01718 (AP), by Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (AP) and by the Alliance Statistics and Data Center (U10-CA33601
- Subjects
Male ,Cardiac Catheterization ,Comparative Effectiveness Research ,Enfermedad cardiovascular ,Named Groups::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings] ,Diseases::Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases::Aortic Valve Stenosis [Medical Subject Headings] ,Severity of Illness Index ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Tratamiento médico ,Prospective Studies ,Registries ,Anciano de 80 o más años ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Hazard ratio ,Pronóstico ,Prognosis ,Cateterismo cardíaco ,Survival Rate ,Treatment Outcome ,Aortic Valve ,Information Science::Information Science::Data Collection::Vital Statistics::Mortality::Cause of Death [Medical Subject Headings] ,Female ,Risk Adjustment ,Aortic surgery ,Estenosis de la válvula aórtica ,Implantación de prótesis de válvulas cardíacas ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Catheterization::Heart Catheterization [Medical Subject Headings] ,Survival Status ,medicine.medical_specialty ,Intervention (counseling) ,Internal Medicine ,medicine ,Humans ,Symptomatic aortic stenosis ,Geriatric Assessment ,business.industry ,Aortic stenosis ,Patient Selection ,Cardiovascular Agents ,Aortic Valve Stenosis ,medicine.disease ,Confidence interval ,Causas de muerte ,Surgery ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Cardiac Surgical Procedures::Heart Valve Prosthesis Implantation [Medical Subject Headings] ,Ageing ,Stenosis ,Spain ,Propensity score matching ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,Observational study ,business - Abstract
OBJECTIVE: To study the factors associated with choice of therapy and prognosis in octogenarians with severe symptomatic aortic stenosis (AS). STUDY DESIGN: Prospective, observational, multicenter registry. Centralized follow-up included survival status and, if possible, mode of death and Katz index. SETTING: Transnational registry in Spain. SUBJECTS: We included 928 patients aged ≥80 years with severe symptomatic AS. INTERVENTIONS: Aortic-valve replacement (AVR), transcatheter aortic-valve implantation (TAVI) or conservative therapy. MAIN OUTCOME MEASURES: All-cause death. RESULTS: Mean age was 84.2 ± 3.5 years, and only 49.0% were independent (Katz index A). The most frequent planned management was conservative therapy in 423 (46%) patients, followed by TAVI in 261 (28%) and AVR in 244 (26%). The main reason against recommending AVR in 684 patients was high surgical risk [322 (47.1%)], other medical motives [193 (28.2%)], patient refusal [134 (19.6%)] and family refusal in the case of incompetent patients [35 (5.1%)]. The mean time from treatment decision to AVR was 4.8 ± 4.6 months and to TAVI 2.1 ± 3.2 months, P < 0.001. During follow-up (11.2-38.9 months), 357 patients (38.5%) died. Survival rates at 6, 12, 18 and 24 months were 81.8%, 72.6%, 64.1% and 57.3%, respectively. Planned intervention, adjusted for multiple propensity score, was associated with lower mortality when compared with planned conservative treatment: TAVI Hazard ratio (HR) 0.68 (95% confidence interval [CI] 0.49-0.93; P = 0.016) and AVR HR 0.56 (95% CI 0.39-0.8; P = 0.002). CONCLUSION: Octogenarians with symptomatic severe AS are frequently managed conservatively. Planned conservative management is associated with a poor prognosis.
- Published
- 2013
15. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: A population-based study in a Mediterranean area
- Author
-
Ferreira-González I., Pinar-Sopena J., Ribera A., Marsal J.R., Cascant P., González-Alujas T., Evangelista A., Brotons C., Moral I., Permanyer-Miralda G., García-Dorado D., and Tornos P.
- Subjects
cardiovascular risk factors ,Male ,obesity ,aorta valve ,very elderly ,aortic valve stenosis ,aorta valve stenosis ,Comorbidity ,Severity of Illness Index ,Peripheral Arterial Disease ,sclerosis ,Risk Factors ,calcinosis ,Odds Ratio ,Prevalence ,cross-sectional study ,Humans ,human ,aortic valve sclerosis ,risk ,Aged, 80 and over ,statistical model ,Smoking ,article ,Age Factors ,calcific aortic valve disease ,aged ,Cross-Sectional Studies ,Logistic Models ,female ,multivariate analysis ,age ,risk factor ,Spain ,Aortic Valve ,Hypertension ,Linear Models ,pathology ,peripheral occlusive artery disease - Abstract
To determine the prevalence of aortic valve sclerosis (ASC) and stenosis (AS) in the elderly in a Mediterranean area and to identify associated clinical factors. Population cross-sectional study in a random sample of 1068 people =65 years in a Mediterranean area. ASC was categorized as absent, mild-to-moderate, or moderate-to-severe depending on the severity of thickening and calcification. The relation between the severity of ASC and potential risk factors was assessed by multinomial logistic regression analysis. Some degree of thickening and/or calcification was present in 45.4%, of the sample, 73.5% in >85 years. AS prevalence was 3% for the total cohort and 7.4% in >85 years. Adjusting for gender it was found that age, smoking habit, hypertension, waist circumference, and ankle–brachial index
- Published
- 2013
16. Degenerative calcific aortic valve disease: from pathogenic to epidemiological characterization
- Author
-
Sánchez, Pedro L., Pompa, José Luis de la, San Román, J. A., García Arroyo, Alicia, Martín Luengo, C., Pinar, J., Ferreira-González, I., Martínez Sellés Oliveria Soares, Manuel, and Tornos, P.
- Subjects
Tratamiento médico ,Enfermedad cardiovascular - Abstract
5.972 JCR (2008) Q1, 5/79 Cardiac & cardiovascular systems
- Published
- 2008
17. Cost-Utility Of Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement In High-Risk Patients With Severe Aortic Stenosis: A Prospective Observational Study
- Author
-
Ribera, A., primary, Ferreira-González, I., additional, Slof, J., additional, Cascant, P., additional, Abdul-Jawad, O., additional, Marsal, J.R., additional, Serra, V., additional, Garcia del Blanco, B., additional, Tornos, P., additional, Sureda, C., additional, Falces, C., additional, Andrea, R., additional, Gutiérrez, E., additional, del Valle, R., additional, Mota, P., additional, Goicolea, J., additional, Permanyer, G., additional, and Garcia-Dorado, D., additional
- Published
- 2014
- Full Text
- View/download PDF
18. PMD73 Quality of Life and Resource Use After Transcatheter Aortic Valve Implantation. Preliminary Results of an Observational Multicentre Study
- Author
-
Ribera, A., primary, Ferreira-González, I., additional, Slof, J., additional, Cascant, P., additional, Abdul-Jawad, O., additional, Marsal, J.R., additional, Garcia del Blanco, B., additional, Serra, V., additional, Falces, C., additional, Andrea, R., additional, Gutiérrez, E., additional, del Valle, R., additional, Mota, P., additional, López, D., additional, Tornos, P., additional, and Garcia-Dorado, D., additional
- Published
- 2012
- Full Text
- View/download PDF
19. PMD25 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) in High-Risk or Inoperable Patients with Symptomatic Aortic Valve Stenosis in Spain
- Author
-
Ferreira-González, I., primary, Serra, V., additional, Abdul, O., additional, Lizan, L., additional, Paz, S., additional, Banz, K., additional, Sureda, C., additional, Igual, A., additional, Garcia del Blanco, B., additional, Angel, J., additional, Garcia-dorado, D., additional, Tornos, P., additional, and Ribera, A., additional
- Published
- 2011
- Full Text
- View/download PDF
20. MD2 - Cost-Utility Of Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement In High-Risk Patients With Severe Aortic Stenosis: A Prospective Observational Study
- Author
-
Ribera, A., Ferreira-González, I., Slof, J., Cascant, P., Abdul-Jawad, O., Marsal, J.R., Serra, V., Garcia del Blanco, B., Tornos, P., Sureda, C., Falces, C., Andrea, R., Gutiérrez, E., del Valle, R., Mota, P., Goicolea, J., Permanyer, G., and Garcia-Dorado, D.
- Published
- 2014
- Full Text
- View/download PDF
21. Long-term outcome of aortic dissection with patent false lumen: predictive role of entry tear size and location.
- Author
-
Evangelista A, Salas A, Ribera A, Ferreira-González I, Cuellar H, Pineda V, González-Alujas T, Bijnens B, Permanyer-Miralda G, Garcia-Dorado D, Evangelista, Artur, Salas, Armando, Ribera, Aida, Ferreira-González, Ignacio, Cuellar, Hug, Pineda, Victor, González-Alujas, Teresa, Bijnens, Bart, Permanyer-Miralda, Gaietà, and Garcia-Dorado, David
- Published
- 2012
- Full Text
- View/download PDF
22. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents.
- Author
-
Ribera A, Ferreira-González I, Marsal JR, Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Iñigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Güemez L, García-Del-Blanco B, Martí G, García-Dorado D, Ribera, Aida, Ferreira-González, Ignacio, Marsal, Josep Ramón, Cascant, Purificación, Permanyer-Miralda, Gaietà, Abdul-Jawad, Omar, and Iñigo-Garcia, Luis Antonio
- Abstract
Advanced atherosclerotic disease increases the risk of stent thrombosis after drug-eluting stent (DES) implantation. We aimed to determine if an abnormal ankle-brachial index (ABI) value as a surrogate of atherosclerotic disease and vascular inflammation provides information on 1-year risk of cardiovascular events after DES implantation. A prospective cohort of 1,437 consecutive patients undergoing DES implantation from January through April 2008 in 26 Spanish hospitals was examined. ABI was calculated by Doppler in a standardized manner. Patients were followed to 12 months after the percutaneous coronary intervention to determine total and cardiovascular mortality, stroke, nonfatal acute coronary syndrome (ACS), and new revascularizations. Association of an abnormal ABI value (i.e., ≤ 0.9 or ≥ 1.4) with outcomes was assessed by conventional logistic regression and by propensity-score analysis. Patients with abnormal ABI values (n = 582, 40.5%) in general had higher global cardiovascular risk, the reason for DES implantation was more often ACS, and had a higher rate of complications during admission (heart failure or stroke or major hemorrhage 11.3% vs 5.3%, p <0.001). An abnormal ABI value was independently associated with 1-year total mortality (odds ratio 2.23, 95% confidence interval 1.13 to 4.4) and cardiovascular mortality (odds ratio 2.06, 95% confidence interval 1.04 to 4.22). No independent association was found between an abnormal ABI value and 1-year nonfatal ACS, stroke, and new revascularizations. In conclusion, although an abnormal ABI value was associated with fatal outcomes in patients receiving DESs, no association was found with nonfatal ACS and new revascularizations. A clear relation between abnormal ABI and surrogates of DES thrombosis could not be established. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. Enoxaparina como tratamiento anticoagulante puente en la cirugía cardíaca.
- Author
-
Rivas-Gándara, N., Ferreira-González, I., Tornos, P., Torrents, A., Permanyer-Miralda, G., Nicolau, I., Arellano-Rodrigo, E., Vallejo, N., Igual, A., and Soler-Soler, J.
- Abstract
Copyright of Heart - Edición Española is the property of Grupo ARS XXI de Comunicacion, S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2008
- Full Text
- View/download PDF
24. Survival, clinical status and quality of life five years after coronary surgery. The ARCA study
- Author
-
Aida Ribera, Ferreira-González I, Cascant P, Jr, Marsal, Romero B, Pedrol D, Martínez-Useros C, Jm, Pons, Fernández T, Permanyer-Miralda G, and Arca, Study Investigators
25. Prognosis and management of patients with acute coronary syndrome and polyvascular disease
- Author
-
Ferreira-González I, Permanyer Miralda G, Heras M, Aida Ribera, Jr, Marsal, Cascant P, Arós F, Bueno H, Pl, Sánchez, Cuñat J, Civeira E, Marrugat J, and Mascara, Investigadores Del Estudio
26. Prospective registry of symptomatic severe aortic stenosis in octogenarians: a need for intervention
- Author
-
Martínez-Sellés, M., Gómez Doblas, J. J., Carro Hevia, A., García de la Villa, B., Ferreira-González, I., Alonso Tello, A., Andión Ogando, R., Ripoll Vera, T., Arribas Jiménez, A., Carrillo, P., Rodriguez Pascual, C., Casares i Romeva, M., Borras, X., Cornide, L., López-Palop, R., Martínez-Sellés, M., Gómez Doblas, J. J., Carro Hevia, A., García de la Villa, B., Ferreira-González, I., Alonso Tello, A., Andión Ogando, R., Ripoll Vera, T., Arribas Jiménez, A., Carrillo, P., Rodriguez Pascual, C., Casares i Romeva, M., Borras, X., Cornide, L., and López-Palop, R.
- Abstract
OBJECTIVE: To study the factors associated with choice of therapy and prognosis in octogenarians with severe symptomatic aortic stenosis (AS). STUDY DESIGN: Prospective, observational, multicenter registry. Centralized follow-up included survival status and, if possible, mode of death and Katz index. SETTING: Transnational registry in Spain. SUBJECTS: We included 928 patients aged ≥80 years with severe symptomatic AS. INTERVENTIONS: Aortic-valve replacement (AVR), transcatheter aortic-valve implantation (TAVI) or conservative therapy. MAIN OUTCOME MEASURES: All-cause death. RESULTS: Mean age was 84.2 ± 3.5 years, and only 49.0% were independent (Katz index A). The most frequent planned management was conservative therapy in 423 (46%) patients, followed by TAVI in 261 (28%) and AVR in 244 (26%). The main reason against recommending AVR in 684 patients was high surgical risk [322 (47.1%)], other medical motives [193 (28.2%)], patient refusal [134 (19.6%)] and family refusal in the case of incompetent patients [35 (5.1%)]. The mean time from treatment decision to AVR was 4.8 ± 4.6 months and to TAVI 2.1 ± 3.2 months, P < 0.001. During follow-up (11.2-38.9 months), 357 patients (38.5%) died. Survival rates at 6, 12, 18 and 24 months were 81.8%, 72.6%, 64.1% and 57.3%, respectively. Planned intervention, adjusted for multiple propensity score, was associated with lower mortality when compared with planned conservative treatment: TAVI Hazard ratio (HR) 0.68 (95% confidence interval [CI] 0.49-0.93; P = 0.016) and AVR HR 0.56 (95% CI 0.39-0.8; P = 0.002). CONCLUSION: Octogenarians with symptomatic severe AS are frequently managed conservatively. Planned conservative management is associated with a poor prognosis.
27. 'Do GRACE (Global Registry of Acute Coronary events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes?'.
- Author
-
Abu-Assi E, Ferreira-González I, Ribera A, Marsal JR, Cascant P, Heras M, Bueno H, Sánchez PL, Arós F, Marrugat J, García-Dorado D, Peña-Gil C, González-Juanatey JR, and Permanyer-Miralda G
- Published
- 2010
- Full Text
- View/download PDF
28. (407) - Screening of Advanced Heart Failure Features Among Patients with LVEF <35%.
- Author
-
Vila-Sanjuán, S., Ródenas-Alesina, E., Olivella, A., Soriano-Colome, T., Fernandez, A. Mendez, Uribarri, A., and Ferreira-González, I.
- Subjects
- *
HEART failure , *MEDICAL screening - Published
- 2024
- Full Text
- View/download PDF
29. Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
- Author
-
Marta Consegal, Ignasi Barba, Bruno García del Blanco, Imanol Otaegui, José F. Rodríguez-Palomares, Gerard Martí, Bernat Serra, Neus Bellera, Manuel Ojeda-Ramos, Filipa Valente, Maria Ángeles Carmona, Elisabet Miró-Casas, Antonia Sambola, Rosa María Lidón, Jordi Bañeras, José Antonio Barrabés, Cristina Rodríguez, Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Barba I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Faculty of Medicine, University of Vic - Central University of Catalonia (UVicUCC), Vic, Spain. [García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Valente F, Carmona MÁ, Miró-Casas E, Sambola A, Lidón RM, Bañeras J, Barrabés JA] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, CIBERESP, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Reperfusion [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Infart de miocardi ,Multidisciplinary ,Reperfusió (Fisiologia) ,compuestos orgánicos::ácidos carboxílicos::ácidos acíclicos::ácidos dicarboxílicos::succinatos::ácido succínico [COMPUESTOS QUÍMICOS Y DROGAS] ,Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Dicarboxylic Acids::Succinates::Succinic Acid [CHEMICALS AND DRUGS] ,intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::reperfusión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] - Abstract
Cardiovascular biology; Diagnostic markers; Prognostic markers Biología cardiovascular; Marcadores de diagnóstico; Marcadores pronósticos Biologia cardiovascular; Marcadors diagnòstics; Marcadors pronòstics Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by 1H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p
- Published
- 2023
- Full Text
- View/download PDF
30. Myocardial injury after major non-cardiac surgery evaluated with advanced cardiac imaging: a pilot study
- Author
-
Jesús Álvarez-Garcia, Ekaterine Popova, Miquel Vives-Borrás, Miriam de Nadal, Jordi Ordonez-Llanos, Mercedes Rivas-Lasarte, Abdel-Hakim Moustafa, Eduard Solé-González, Pilar Paniagua-Iglesias, Xavier Garcia-Moll, David Viladés-Medel, Rubén Leta-Petracca, Gerard Oristrell, Javier Zamora, Ignacio Ferreira-González, Pablo Alonso-Coello, Francesc Carreras-Costa, Institut Català de la Salut, [Álvarez-Garcia J] Department of Cardiology, Hospital Universitario Ramon y Cajal, Madrid, Spain. Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Madrid, Spain. [Popova E] IIB SANT PAU, Institut d’Investigació Biomèdica Sant Pau, Barcelona, Spain. Centro Cochrane Iberoamericano, Barcelona, Spain. Centro Cochrane Iberoamericano, Barcelona, Spain. [Vives-Borrás M] Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa), Department of Cardiology, Palma, Balearic Islands, Spain. Department of Cardiology, Hospital Universitari Son Espases, Palma, Illes Balears, Spain. [de Nadal M] Servei d’Anestesiologia, Reanimació i Tractament del Dolor i Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ordonez-Llanos J] Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Foundation for Clinical Biochemistry & Molecular Pathology, Barcelona, Spain. [Rivas-Lasarte M] Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain. [Oristrell G] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Cirurgia - Complicacions ,heridas y lesiones::traumatismos torácicos::lesiones cardíacas [ENFERMEDADES] ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, X-Ray Computed::Computed Tomography Angiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Cor - Vàlvules - Ferides i lesions ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada por rayos X::angiografía por tomografía computarizada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Angiografia ,Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications [DISEASES] ,Wounds and Injuries::Thoracic Injuries::Heart Injuries [DISEASES] ,Cor - Imatgeria ,Cardiology and Cardiovascular Medicine ,afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias [ENFERMEDADES] - Abstract
Background Myocardial injury after non-cardiac surgery (MINS) is a frequent complication caused by cardiac and non-cardiac pathophysiological mechanisms, but often it is subclinical. MINS is associated with increased morbidity and mortality, justifying the need to its diagnose and the investigation of their causes for its potential prevention. Methods Prospective, observational, pilot study, aiming to detect MINS, its relationship with silent coronary artery disease and its effect on future adverse outcomes in patients undergoing major non-cardiac surgery and without postoperative signs or symptoms of myocardial ischemia. MINS was defined by a high-sensitive cardiac troponin T (hs-cTnT) concentration > 14 ng/L at 48–72 h after surgery and exceeding by 50% the preoperative value; controls were the operated patients without MINS. Within 1-month after discharge, cardiac computed tomography angiography (CCTA) and magnetic resonance imaging (MRI) studies were performed in MINS and control subjects. Significant coronary artery disease (CAD) was defined by a CAD-RADS category ≥ 3. The primary outcomes were prevalence of CAD among MINS and controls and incidence of major cardiovascular events (MACE) at 1-year after surgery. Secondary outcomes were the incidence of individual MACE components and mortality. Results We included 52 MINS and 12 controls. The small number of included patients could be attributed to the study design complexity and the dates of later follow-ups (amid COVID-19 waves). Significant CAD by CCTA was equally found in 20 MINS and controls (30% vs 33%, respectively). Ischemic patterns (n = 5) and ischemic segments (n = 2) depicted by cardiac MRI were only observed in patients with MINS. One-year MACE were also only observed in MINS patients (15.4%). Conclusion This study with advanced imaging methods found a similar CAD frequency in MINS and control patients, but that cardiac ischemic findings by MRI and worse prognosis were only observed in MINS patients. Our results, obtained in a pilot study, suggest the need of further, extended studies that screened systematically MINS and evaluated its relationship with cardiac ischemia and poor outcomes. Trial registration Clinicaltrials.gov identifier: NCT03438448 (19/02/2018).
- Published
- 2023
- Full Text
- View/download PDF
31. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
- Author
-
Josep Ramon Marsal, Iratxe Urreta-Barallobre, Marimar Ubeda-Carrillo, Dimelza Osorio, Blanca Lumbreras, David Lora, Borja M. Fernández-Felix, Gerard Oristrell, Eduard Ródenas-Alesina, Lorena Herrador, Mónica Ballesteros, Javier Zamora, Jose I. Pijoan, Aida Ribera, Ignacio Ferreira-González, Institut Català de la Salut, [Marsal JR, Ribera A, Ferreira-González I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER Epidemiology and Public Health, Madrid, Spain. [Urreta-Barallobre I] CIBER Epidemiology and Public Health, Madrid, Spain. Biodonostia Health Research Institute, Clinical Epidemiology, San Sebastián, Spain. Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain. [Ubeda-Carrillo M] Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Library Service, San Sebastián, Spain. [Osorio D, Ballesteros M] CIBER Epidemiology and Public Health, Madrid, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Lumbreras B] CIBER Epidemiology and Public Health, Madrid, Spain. Public Health Department, Miguel Hernandez University, Alicante, Spain. [Lora D] CIBER Epidemiology and Public Health, Madrid, Spain. Health Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain. Statistical Studies Department, Universidad Complutense de Madrid (UCM), Madrid, Spain. [Oristrell G] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER Cadiovascular Diseases, Madrid, Spain. [Ródenas-Alesina E] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Infart de miocardi - Diagnòstic ,Sample Size ,Myocardial Infarction ,técnicas de investigación::métodos epidemiológicos::diseño de la investigación epidemiológica::tamaño de la muestra [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Humans ,Medicine (miscellaneous) ,Pharmacology (medical) ,Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Sample Size [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Cardiovascular System ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] - Abstract
Background The real impact of the degree of association (DoA) between endpoint components of a composite endpoint (CE) on sample size requirement (SSR) has not been explored. We estimate the impact of the DoA between death and acute myocardial infarction (AMI) on SSR of trials using use the CE of major adverse cardiac events (MACE). Methods A systematic review and quantitative synthesis of trials that include MACE as the primary outcome through search strategies in MEDLINE and EMBASE electronic databases. We limited to articles published in journals indexed in the first quartile of the Cardiac & Cardiovascular Systems category (Journal Citation Reports, 2015–2020). The authors were contacted to estimate the DoA between death and AMI using joint probability and correlation. We analyzed the SSR variation using the DoA estimated from RCTs. Results Sixty-three of 134 publications that reported event rates and the therapy effect in all component endpoints were included in the quantitative synthesis. The most frequent combination was death, AMI, and revascularization (n = 20; 31.8%). The correlation between death and AMI, estimated from 5 trials¸ oscillated between − 0.02 and 0.31. SSR varied from 14,602 in the scenario with the strongest correlation to 12,259 in the scenario with the weakest correlation; the relative impact was 16%. Conclusions The DoA between death and AMI is highly variable and may lead to a considerable SSR variation in a trial including MACE.
- Published
- 2022
- Full Text
- View/download PDF
32. Association of renin–angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study
- Author
-
Soler, María José, Ribera, Aida, Marsal, Josep Ramon, Méndez, Ana Belen, Andrés Villareal, Mireia, Azancot, María A, Oristrell, Gerard, Méndez-Boo, Leonardo, Cohen, Jordana, Barrabés, José A, Ferreira-González, Ignacio, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Soler MJ, Azancot MA] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ribera A, Marsal JR] Servei de Cardiologia, Unitat d'Epidemiologia Cardiovascular, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Mendez AB, Oristrell G] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Andres M, Barrabés JA] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Méndez-Boo L] Departament de Salut, SISAP: Sistema d’Informació dels Serveis d’Atenció Primària, Direcció de Sistemes d’Informació, Institut Català de la Salut, Generalitat de Catalunya, Barcelona, Spain. [Cohen J] Division of Renal-Electrolyte and Hypertension, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA. [Ferreira-González I] Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Angiotensines ,medicine.medical_specialty ,hypertension ,Renin-angiotensin system blockers ,Coronavirus disease 2019 (COVID-19) ,COVID-19 (Malaltia) - Mortalitat ,Cardiovascular Diseases::Vascular Diseases::Hypertension [DISEASES] ,Internal medicine ,Renin–angiotensin system ,Medicine ,In patient ,cardiovascular diseases ,Mortality ,AcademicSubjects/MED00340 ,angiotensin converting enzyme ,Transplantation ,business.industry ,COVID-19 ,renin-angiotensin system blockers ,Angiotensin receptor blockers ,mortality ,angiotensin receptor blockers ,Population based study ,Nephrology ,Hypertension ,Original Article ,Hipertensió ,business ,enfermedades cardiovasculares::enfermedades vasculares::hipertensión [ENFERMEDADES] ,Angiotensin-converting enzyme - Abstract
Background The effect of renin-angiotensin(RAS) blockade either by angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) on coronavirus disease 2019(COVID-19) susceptibility, mortality and severity is inadequately described. We examined the association between renin-angiotensin system (RAS) blockade and COVID-19 diagnosis and prognosis in a large population-based cohort of patients with hypertension. Methods This is a cohort study using regional health records. We identified all individuals aged 18-95 years from 87 health care reference areas of the main health provider in Catalonia(Spain), with a history of hypertension from primary care records. Data were linked to COVID-19 test results, hospital, pharmacy and mortality records from 1 March 2020 to 14 August 2020. We defined exposure to RAS blockers as the dispensation of ACEi/ARBs during the three months before COVID-19 diagnosis or 1 March 2020. Primary outcomes were: COVID-19 infection, and severe progression in hospitalized patients with COVID-19(the composite of need for invasive respiratory support or death). For both outcomes and for each exposure of interest (RAAS blockade, ACEi or ARB) we estimated associations in age-sex-area-propensity matched samples. Results From a cohort of 1,365,215 inhabitants we identified 305,972 patients with hypertension history. Recent use of ACEi/ARBs in patients with hypertension was associated with a lower 6 month-cumulative incidence of COVID-19 diagnosis (3.78% [95% CI: 3.69% - 3.86%] vs 4.53% [95% CI: 4.40% - 4.65%]; p, Graphical Abstract Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
33. A Case of a Young Patient with Acute Endocarditis and Challenging Diagnostic and Treatment Decisions
- Author
-
Teresa González-Alujas, Carlos Sureda, Albert Roque, Antonia Sambola, Gerard Oristrell, Pau Rello, Toni Soriano-Colomé, Laura Escolà-Vergé, Ignacio Ferreira-González, Institut Català de la Salut, [Rello P, González-Alujas T, Soriano-Colomé T, Oristrell G, Sambola A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Escolà-Vergé L] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Roque A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institut de Diagnòstic per la Imatge (IDI), Barcelona, Spain. [Sureda C] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cirurgia Cardíaca, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_specialty ,business.industry ,infecciones bacterianas y micosis::infección::infecciones relacionadas con prótesis [ENFERMEDADES] ,Bacterial Infections and Mycoses::Bacterial Infections::Endocarditis, Bacterial [DISEASES] ,infecciones bacterianas y micosis::infecciones bacterianas::endocarditis bacteriana [ENFERMEDADES] ,Infectious Diseases ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Cardiovascular [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Acute Endocarditis ,Bacterial Infections and Mycoses::Infection::Prosthesis-Related Infections [DISEASES] ,diagnóstico::técnicas y procedimientos diagnósticos::técnicas diagnósticas cardiovasculares [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,medicine ,Pròtesis ,Treatment decision making ,Cor - Imatgeria ,Endocarditis bacteriana - Diagnòstic ,Intensive care medicine ,business - Abstract
Endocarditis infecciosa; Endocarditis protésica Endocarditis infecciosa; Endocarditis protèsica Infective endocarditis; Prosthetic endocarditis Despite advances achieved in recent years, Infective Endocarditis (IE) remains a disease associated with high mortality and morbidity. When it involves multiple locations at the same time, deciding the best treatment can become challenging. In some cases, especially in patients with prosthetic valve endocarditis, a definitive diagnosis can be difficult to achieve and multimodality imaging including Positron Emission Tomography/Computed Tomography Angiography (PET/CTA) has demonstrated improvement in the diagnostic yield. We present a case of a young patient with two previous thoracic surgeries who was admitted due to a severe Staphylococcus aureus IE affecting the mitral valve and presenting a questionable image in an aortic arch graft. This case illustrates the importance of the Endocarditis Team when it comes to difficult decisions regarding diagnosis and management in a disease with poor scientific evidence.
- Published
- 2021
- Full Text
- View/download PDF
34. Defective dimerization of FoF1‐ATP synthase secondary to glycation favors mitochondrial energy deficiency in cardiomyocytes during aging
- Author
-
Diana Bou‐Teen, Celia Fernandez‐Sanz, Elisabet Miro‐Casas, Zuzana Nichtova, Elena Bonzon‐Kulichenko, Kelly Casós, Javier Inserte, Antonio Rodriguez‐Sinovas, Begoña Benito, Shey‐Shing Sheu, Jesús Vázquez, Ignacio Ferreira‐González, Marisol Ruiz‐Meana, Instituto de Salud Carlos III, Ministerio de Salud (España), Sociedad Española de Cardiología, Institut Català de la Salut, [Bou-Teen D, Miro-Casas E, Casós K, Inserte J, Rodriguez-Sinovas A, Benito B, Ruiz-Meana M] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Fernandez-Sanz C, Sheu SS] Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, USA. [Nichtova Z] MitoCare Center for Mitochondrial Imaging Research and Diagnostics, Department of Pathology, Anatomy & Cell Biol., Thomas Jefferson University, Philadelphia, USA. [Bonzon-Kulichenko E, Vázquez J] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. Cardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Glycation End Products, Advanced ,Aging ,Mitochondrial Permeability Transition Pore ,Other subheadings::Other subheadings::/metabolism [Other subheadings] ,Cell Biology ,Mitochondrial Proton-Translocating ATPases ,Mitochondria, Heart ,Mice ,Adenosine Triphosphate ,Animals ,Myocytes, Cardiac ,Calcium ,Mitocondris - Malalties ,Cèl·lules - Envelliment ,células::estructuras celulares::espacio intracelular::citoplasma::estructuras citoplasmáticas::orgánulos::mitocondrias::mitocondrias musculares::mitocondrias cardíacas [ANATOMÍA] ,Dimerization ,Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria::Mitochondria, Muscle::Mitochondria, Heart [ANATOMY] ,Otros calificadores::Otros calificadores::/metabolismo [Otros calificadores] - Abstract
Aging; Dicarbonyl stress; Mitochondria Envelliment; Estrès dicarbonílic; Mitocondris Envejecimiento; Estrés dicarbonílico; Mitocondrias Aged cardiomyocytes develop a mismatch between energy demand and supply, the severity of which determines the onset of heart failure, and become prone to undergo cell death. The FoF1-ATP synthase is the molecular machine that provides >90% of the ATP consumed by healthy cardiomyocytes and is proposed to form the mitochondrial permeability transition pore (mPTP), an energy-dissipating channel involved in cell death. We investigated whether aging alters FoF1-ATP synthase self-assembly, a fundamental biological process involved in mitochondrial cristae morphology and energy efficiency, and the functional consequences this may have. Purified heart mitochondria and cardiomyocytes from aging mice displayed an impaired dimerization of FoF1-ATP synthase (blue native and proximity ligation assay), associated with abnormal mitochondrial cristae tip curvature (TEM). Defective dimerization did not modify the in vitro hydrolase activity of FoF1-ATP synthase but reduced the efficiency of oxidative phosphorylation in intact mitochondria (in which membrane architecture plays a fundamental role) and increased cardiomyocytes’ susceptibility to undergo energy collapse by mPTP. High throughput proteomics and fluorescence immunolabeling identified glycation of 5 subunits of FoF1-ATP synthase as the causative mechanism of the altered dimerization. In vitro induction of FoF1-ATP synthase glycation in H9c2 myoblasts recapitulated the age-related defective FoF1-ATP synthase assembly, reduced the relative contribution of oxidative phosphorylation to cell energy metabolism, and increased mPTP susceptibility. These results identify altered dimerization of FoF1-ATP synthase secondary to enzyme glycation as a novel pathophysiological mechanism involved in mitochondrial cristae remodeling, energy deficiency, and increased vulnerability of cardiomyocytes to undergo mitochondrial failure during aging. This work was supported by the Instituto de Salud Carlos III of the Spanish Ministry of Health (FIS-PI19-01196) and a grant from the Sociedad Española de Cardiología (SEC/FEC-INV-BAS 217003)
- Published
- 2022
- Full Text
- View/download PDF
35. Dynamics of Emergency Cardiovascular Hospital Admissions and In-Hospital Mortality During the COVID-19 Pandemic: Time Series Analysis and Impact of Socioeconomic Factors
- Author
-
Claudia Álvarez-Martín, Aida Ribera, Josep Ramon Marsal, Albert Ariza-Solé, Santiago Pérez-Hoyos, Gerard Oristrell, Toni Soriano-Colomé, Rafael Romaguera, Jose Ignacio Pijoan, Rosa M. Lidón, Josepa Mauri, Ignacio Ferreira-González, Institut Català de la Salut, [Álvarez-Martín C, Marsal JR] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Ribera A] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Recerca en Envelliment, Fragilitat i Transicions (REFiT) Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d’Hebron Institute of Research, Barcelona, Spain. [Ariza-Solé A] Cardiology Department, Hospital Universitari de Bellvitge, Barcelona, Spain. Bioheart, Grup de Malalties Cardiovasculars, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Pérez-Hoyos S] Unitat d'Estadística i Bioinformàtica (UEB), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Statistics Department, Faculty of Biology, University of Barcelona, Barcelona, Spain. [Oristrell G, Lidón RM] Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Soriano-Colomé T] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferreira-González I] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad [Otros calificadores] ,Cardiovascular Diseases [DISEASES] ,epidemiología y bioestadística::bioestadística::datos demográficos::estadísticas vitales::mortalidad::mortalidad hospitalaria [SALUD PÚBLICA] ,Cardiac patients ,COVID-19 ,Heart failure ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,COVID-19 (Malaltia) ,Epidemiology and Biostatistics::Biostatistics::Demographic Data::Vital Statistics::Mortality::Hospital Mortality [PUBLIC HEALTH] ,Malalts cardíacs ,Myocardial infarction ,Economic conditions ,Mortalitat - Estadístiques ,Other subheadings::Other subheadings::Other subheadings::/mortality [Other subheadings] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Condicions econòmiques ,Acute coronary syndrome ,Time-series ,Cardiology and Cardiovascular Medicine ,Sistema cardiovascular - Malalties - Mortalitat ,enfermedades cardiovasculares [ENFERMEDADES] - Abstract
COVID-19; Síndrome coronario agudo; Insuficiencia cardiaca COVID-19; Síndrome coronària aguda; Insuficiència cardíaca COVID-19; Acute coronary syndrome; Heart failure Aims: This study aimed to evaluate the decline in urgent cardiovascular hospital admissions and in-hospital mortality during the COVID pandemic in two successive waves, and to evaluate differences by sex, age, and deprivation index subgroups. Methods and Results: We obtained acute cardiovascular hospital episodes during the years 2019–2020 from region-wide data on public healthcare usage for the population of Catalonia (North-East Spain). We fitted time models to estimate the incidence rate ratios (IRRs) of the acute coronary syndrome (ACS) and acute heart failure (HF) admissions during the first pandemic wave, the between-waves period, and the second wave compared with the corresponding pre-COVID-19 periods and to test for the interaction with sex, age, and area-based socioeconomic level. We evaluated the effect of COVID-19 period on in-hospital mortality. ACS (n = 8,636) and HF (n = 27,566) episodes were defined using primary diagnostic ICD-10 codes. ACS and HF admissions decreased during the first wave (IRR = 0.66, 95%CI: 0.58–0.76 and IRR = 0.61, 95% CI: 0.55–0.68, respectively) and during the second wave (IRR = 0.80, 95%CI: 0.72–0.88 and IRR = 0.76, 95%CI: 0.69–0.84, respectively); acute HF admissions also decreased in the period between waves (IRR: 0.81, 95%CI: 0.74–0.89). The impact was similar in all sex and socioeconomic subgroups and was higher in older patients with ACS. In-hospital mortality was higher than expected only during the first wave. Conclusion: During the first wave of the COVID-19 pandemic, there was a marked decline in urgent cardiovascular hospital admissions that were attenuated during the second wave. Both the decline and the attenuation of the effect have been similar in all subgroups regardless of age, sex, or socioeconomic status. In-hospital mortality for ACS and HF episodes increased during the first wave, but not during the second wave. This study was funded with a grant from Sociedad Española de Cardiología y Fundación Española del Corazón (SEC/FEC-INV-CLI 21/017). The funder had no role in the study development.
- Published
- 2022
36. The valve uptake index: improving assessment of prosthetic valve endocarditis and updating [18F]FDG PET/CT(A) imaging criteria
- Author
-
Albert Roque, María N Pizzi, Nuria Fernández-Hidalgo, Guillermo Romero-Farina, Gemma Burcet, José Luis Reyes-Juarez, Carina Espinet, Joan Castell-Conesa, Manuel Escobar, Ignacio Ferreira-González, Santiago Aguadé-Bruix, Hug Cuellar-Calabria, Institut Català de la Salut, [Roque A, Burcet G, Reyes-Juarez JL, Cuellar-Calabria H] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Pizzi MN] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Fernández-Hidalgo N] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Romero-Farina G] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Espinet C, Castell-Conesa J] IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escobar M] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. [Ferreira-González I] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Epidemiologıa y Salud Pública (CIBERESP), Madrid, Spain. [Aguadé-Bruix S] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Endocarditis bacteriana - Imatgeria ,Pròtesis valvulars cardíaques ,Prosthesis-Related Infections ,Endocarditis ,infecciones bacterianas y micosis::infección::infecciones relacionadas con prótesis [ENFERMEDADES] ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada por rayos X::angiografía por tomografía computarizada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,General Medicine ,Endocarditis, Bacterial ,Fluorodeoxyglucose F18 ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, X-Ray Computed::Computed Tomography Angiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Heart Valve Prosthesis ,Positron Emission Tomography Computed Tomography ,Cardiovascular Diseases::Heart Diseases::Endocarditis [DISEASES] ,Bacterial Infections and Mycoses::Infection::Prosthesis-Related Infections [DISEASES] ,Humans ,Radiology, Nuclear Medicine and imaging ,Tomografia per emissió de positrons ,enfermedades cardiovasculares::enfermedades cardíacas::endocarditis [ENFERMEDADES] ,Radiopharmaceuticals ,Cardiology and Cardiovascular Medicine ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Retrospective Studies - Abstract
Aims Diagnosis of prosthetic valve endocarditis (PVE) by positron emission computed tomography angiography (PET/CTA) is based on visual and quantitative morpho-metabolic features. However, the fluorodeoxyglucose (FDG) uptake pattern can be sometimes visually unclear and susceptible to subjectivity. This study aimed to validate a new parameter, the valve uptake index [VUI, maximum standardized uptake value (SUVmax)−mean standardized uptake value (SUVmean)/SUVmax], designed to provide a more objective indication of the distribution of metabolic activity. Secondly, to re-evaluate the utility of traditionally used PVE imaging criteria and determine the potential value of adding the VUI in the diagnostic algorithm of PVE. Methods and results Retrospective analysis of 122 patients (135 prosthetic valves) admitted for suspicion of endocarditis, with a conclusive diagnosis of definite (N = 57) or rejected (N = 65) PVE, and who had undergone a cardiac PET/CTA scan as part of the diagnostic evaluation. We measured the VUI and recorded the SUVmax, SUVratio, uptake pattern, and the presence of endocarditis-related anatomic lesions. The VUI, SUVmax, and SUVratio values were 0.54 ± 0.1 vs. 0.36 ± 0.08, 7.68 ± 3.07 vs. 3.72 ± 1.11, and 4.28 ± 1.93 vs. 2.16 ± 0.95 in the ‘definite’ PVE group vs. the ‘rejected’ group, respectively (mean ± SD; P < 0.001). A cut-off value of VUI > 0.45 showed a sensitivity, specificity, and diagnostic accuracy for PVE of 85%, 88%, and 86.7% and increased diagnostic ability for confirming endocarditis when combined with the standard diagnostic criteria. Conclusions The VUI demonstrated good diagnostic accuracy for PVE, even increasing the diagnostic power of the traditionally used morphometabolic parameters, which also confirmed their own diagnostic performance. More research is needed to assess whether the integration of the VUI into the PVE diagnostic algorithm may clarify doubtful cases and thus improve the diagnostic yield of PET/CTA.
- Published
- 2021
37. Citric Acid Cycle Metabolites Predict Infarct Size in Pigs Submitted to Transient Coronary Artery Occlusion and Treated with Succinate Dehydrogenase Inhibitors or Remote Ischemic Perconditioning
- Author
-
Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Norberto Núñez, Marta Consegal, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Ignasi Barba, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Núñez N] Unitat d'Alta Tecnologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Barba I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann. Ctra. de Roda, 70, 08500 Vic, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Swine ,Endogeny ,030204 cardiovascular system & hematology ,Pharmacology ,ischemia-reperfusion ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Dicarboxylic Acids ,Myocardial infarction ,Biology (General) ,Enzyme Inhibitors ,Ischemic Preconditioning ,Spectroscopy ,remote ischemic conditioning ,biology ,Àcid cítric - Metabolisme ,Chemistry ,Succinate dehydrogenase ,Ischemia-reperfusion ,metabolismo::metabolismo energético::metabolismo::ciclo del ácido cítrico [FENÓMENOS Y PROCESOS] ,Remote ischemic conditioning ,Heart ,General Medicine ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Computer Science Applications ,Malonate ,myocardial infarction ,Other subheadings::Other subheadings::/administration & dosage [Other subheadings] ,sustancias macromoleculares::complejos multiproteicos::complejos multienzimáticos::succinato citocromo c oxidorreductasa::complejo II de transporte de electrones::succinato deshidrogenasa [COMPUESTOS QUÍMICOS Y DROGAS] ,QH301-705.5 ,Sodium ,Citric Acid Cycle ,chemistry.chemical_element ,Catalysis ,Great cardiac vein ,Article ,Inorganic Chemistry ,03 medical and health sciences ,Metabolism::Energy Metabolism::Metabolism::Citric Acid Cycle [PHENOMENA AND PROCESSES] ,medicine ,Animals ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,Macromolecular Substances::Multiprotein Complexes::Multienzyme Complexes::Succinate Cytochrome c Oxidoreductase::Electron Transport Complex II::Succinate Dehydrogenase [CHEMICALS AND DRUGS] ,Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores] ,Myocardium ,Organic Chemistry ,medicine.disease ,succinate dehydrogenase ,malonate ,Citric acid cycle ,Infart de miocardi ,030104 developmental biology ,Coronary Occlusion ,Inhibidors enzimàtics ,Coronary occlusion ,biology.protein ,Biomarkers - Abstract
Succinate dehydrogenase (SDH) inhibition with malonate during reperfusion reduced myocardial infarction in animals, whereas its endogenous substrate, succinate, is detected in plasma from STEMI patients. We investigated whether protection by SDH inhibition is additive to that of remote ischemic perconditioning (RIC) in pigs submitted to transient coronary artery occlusion, and whether protective maneuvers influence plasma levels of citric acid cycle metabolites. Forty pigs were submitted to 40 min coronary occlusion and reperfusion, and allocated to four groups (controls, sodium malonate 10 mmol/L, RIC, and malonate + RIC). Plasma was obtained from femoral and great cardiac veins and analyzed by LC-MS/MS. Malonate, RIC, and malonate + RIC reduced infarct size (24.67 ± 5.98, 25.29 ± 3.92 and 29.83 ± 4.62% vs. 46.47 ± 4.49% in controls, p <, 0.05), but no additive effects were detected. Enhanced concentrations of succinate, fumarate, malate and citrate were observed in controls during initial reperfusion in the great cardiac vein, and most were reduced by cardioprotective maneuvers. Concentrations of succinate, fumarate, and malate significantly correlated with infarct size. In conclusion, despite the combination of SDH inhibition during reperfusion and RIC did not result in additive protection, plasma concentrations of selected citric acid cycle metabolites are attenuated by protective maneuvers, correlate with irreversible injury, and might become a prognosis tool in STEMI patients.
- Published
- 2021
38. Diagnostic value of quantitative parameters for myocardial perfusion assessment in patients with suspected coronary artery disease by single- and dual-energy computed tomography myocardial perfusion imaging
- Author
-
Andrea Guala, Laura Gutiérrez, Teresa González-Alujas, Arturo Evangelista, Lydia Dux-Santoy, Gisela Teixido-Tura, José Rodríguez-Palomares, Laura Galian-Gay, Ignacio Ferreira-González, Guillem Casas, Aroa Ruiz-Muñoz, Rubén Fernández-Galera, Filipa Valente, Institut Català de la Salut, [Ruiz-Muñoz A, Valente F, Dux-Santoy L, Guala A, Teixidó-Turà G, Galián-Gay L, Gutiérrez L, Fernández-Galera R, Casas G, González-Alujas T, Evangelista A, Rodríguez-Palomares J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferreira-González I] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERESP, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
lcsh:Diseases of the circulatory (Cardiovascular) system ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Coronary Disease::Coronary Artery Disease [DISEASES] ,Tomografia computada per emissió de fotó simple ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedad coronaria::enfermedad arterial coronaria [ENFERMEDADES] ,Perfusion scanning ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::técnicas de imagen cardíaca::imágenes de perfusión miocárdica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,030204 cardiovascular system & hematology ,Myocardial ischaemia ,Malalties coronàries ,Coronary artery disease ,03 medical and health sciences ,Myocardial perfusion imaging ,0302 clinical medicine ,medicine ,In patient ,030212 general & internal medicine ,CT myocardial perfusion imaging ,Original Paper ,Receiver operating characteristic ,medicine.diagnostic_test ,business.industry ,Transmural perfusion ratio ,Estimació de paràmetres ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Cardiac Imaging Techniques::Myocardial Perfusion Imaging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Dual-Energy Computed Tomography ,medicine.disease ,Environmental Health::General Aspects::Parameters [PUBLIC HEALTH] ,lcsh:RC666-701 ,Concomitant ,salud ambiental::aspectos generales::parámetros [SALUD PÚBLICA] ,Dual-energy CT-based iodine imaging ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,Perfusion - Abstract
Imatge de perfusió miocàrdica per TC; Isquèmia miocàrdica; Relació de perfusió transmural CT myocardial perfusion imaging; Myocardial ischaemia; Transmural perfusion ratio Imágenes de perfusión miocárdica por TC; Isquemia miocárdica; Relación de perfusión transmural Purpose To compare performance of visual and quantitative analyses for detecting myocardial ischaemia from single- and dual-energy computed tomography (CT) in patients with suspected coronary artery disease (CAD). Methods Eighty-four patients with suspected CAD were scheduled for dual-energy cardiac CT at rest (CTA) and pharmacological stress (CTP). Myocardial CT perfusion was analysed visually and using three parameters: mean attenuation density (MA), transmural perfusion ratio (TPR) and myocardial perfusion reserve index (MPRI), on both single-energy CT and CT-based iodine images. Significant CAD was defined in AHA-segments by concomitant myocardial hypoperfusion identified visually or quantitatively (parameter < threshold) and coronary stenosis detected by CTA. Single-photon emission CT and invasive coronary angiography were used as reference. Perfusion-parameter cut-off values were calculated in a randomly-selected subgroup of 30 patients. Results The best-performing thresholds for TPR, MPRI and MA were 0.96, 23 and 0.5 for single-energy CT and 0.97, 47 and 0.3 for iodine imaging. For both CT-imaging modalities, TPR yielded the highest area under receiver operating characteristic curve (AUC) (0.99 and 0.97 for single-energy CT and iodine imaging, respectively, in vessel-based analysis) compared to visual analysis, MA and MPRI. Visual interpretation on iodine imaging resulted in higher AUC compared to that on single-energy CT in per-vessel (AUC: 0.93 vs 0.86, respectively) and per-patient (0.94 vs 0.93) analyses. Conclusion Transmural perfusion ratio on both CT-imaging modalities is the best-performing parameter for detecting myocardial ischaemia compared to visual method and other perfusion parameters. Visual analysis on CT-based iodine imaging outperforms that on single-energy CT.
- Published
- 2021
39. Connexins in the Heart : Regulation, Function and Involvement in Cardiac Disease
- Author
-
Ignacio Ferreira-González, Laura Valls-Lacalle, Marta Consegal, José Antonio Sánchez Sánchez, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Rodríguez-Sinovas A, Sánchez JA, Valls-Lacalle L, Consegal M] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,connexin ,Other subheadings::Other subheadings::/physiopathology [Other subheadings] ,Cardiac fibrosis ,Gap junction ,Connexines - Metabolisme ,Connexin ,cardiomyocyte ,Review ,030204 cardiovascular system & hematology ,Mitochondrion ,Connexins ,0302 clinical medicine ,Biology (General) ,Spectroscopy ,Otros calificadores::Otros calificadores::/metabolismo [Otros calificadores] ,Cardioprotection ,Other subheadings::Other subheadings::/metabolism [Other subheadings] ,Heart ,General Medicine ,Computer Science Applications ,Cell biology ,Cx43 ,Mitochondria ,mitochondria ,Cardiovascular Diseases::Heart Diseases [DISEASES] ,Chemistry ,Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Membrane Transport Proteins::Connexins [CHEMICALS AND DRUGS] ,Cor - Fisiologia patològica ,Otros calificadores::Otros calificadores::/fisiopatología [Otros calificadores] ,Heart Diseases ,hemichannel ,QH301-705.5 ,Ischemia ,heart ,Cardiomyocyte ,Biology ,enfermedades cardiovasculares::enfermedades cardíacas [ENFERMEDADES] ,Hemichannel ,Catalysis ,aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::proteínas de transporte de membrana::conexinas [COMPUESTOS QUÍMICOS Y DROGAS] ,Nucleus ,Inorganic Chemistry ,gap junction ,03 medical and health sciences ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Cor - Malalties ,QD1-999 ,Organic Chemistry ,nucleus ,medicine.disease ,030104 developmental biology ,Reperfusion injury ,Homeostasis - Abstract
Cardiomiòcit; Connexina; Mitocondris Cardiomiocito; Conexina; Mitocondrias Cardiomyocyte; Connexin; Mitochondria Connexins are a family of transmembrane proteins that play a key role in cardiac physiology. Gap junctional channels put into contact the cytoplasms of connected cardiomyocytes, allowing the existence of electrical coupling. However, in addition to this fundamental role, connexins are also involved in cardiomyocyte death and survival. Thus, chemical coupling through gap junctions plays a key role in the spreading of injury between connected cells. Moreover, in addition to their involvement in cell-to-cell communication, mounting evidence indicates that connexins have additional gap junction-independent functions. Opening of unopposed hemichannels, located at the lateral surface of cardiomyocytes, may compromise cell homeostasis and may be involved in ischemia/reperfusion injury. In addition, connexins located at non-canonical cell structures, including mitochondria and the nucleus, have been demonstrated to be involved in cardioprotection and in regulation of cell growth and differentiation. In this review, we will provide, first, an overview on connexin biology, including their synthesis and degradation, their regulation and their interactions. Then, we will conduct an in-depth examination of the role of connexins in cardiac pathophysiology, including new findings regarding their involvement in myocardial ischemia/reperfusion injury, cardiac fibrosis, gene transcription or signaling regulation. This work was supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (grants PI17/01397 and CIBERCV), and the Spanish Society of Cardiology (Proyectos de la FEC para Investigación Básica en Cardiología 2018, Sociedad Española de Cardiología), Fundació La Marató de TV3 (Nº. 201536-10) and was cofinanced by the European Regional Development Fund (ERDF-FEDER, a way to build Europe). Antonio Rodríguez-Sinovas has a consolidated Miguel Servet contract.
- Published
- 2021
40. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction
- Author
-
Jordi Bañeras, Filipa Valente, Ignacio Ferreira-González, Imanol Otaegui, Ana Sánchez, Laura Castellote, Begoña Benito, Agnès Rafecas, José A. Barrabés, Javier Inserte, José Rodríguez-Palomares, Antonio Rodríguez-Sinovas, Victor Pineda, Elisabet Miró-Casas, Sara Delgado-Tomas, David Beneítez, Rosa-Maria Lidón, Irene Buera, Laia Milà, Antonia Sambola, David Aluja, Marisol Ruiz-Meana, Institut Català de la Salut, [Inserte J, Barrabés JA, Aluja D, Otaegui I, Bañeras J, Sánchez A, Rodríguez-Palomares JF, Miró-Casas E, Milà L, Lidón RM, Sambola A, Valente F, Rafecas A, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Buera I, Delgado-Tomás S, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Castellote L] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Beneítez D] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_treatment ,myocardial reperfusion ,intervenciones quirúrgicas::intervenciones quirúrgicas::procedimientos quirúrgicos mínimamente invasivos::procedimientos endovasculares::cirugía coronaria percutánea [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,iron deficiency ,CMR, cardiac magnetic resonance ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica [ENFERMEDADES] ,ID, iron deficiency ,Myocardial infarction ,sGC, soluble guanylyl cyclase ,Malalties coronàries - Cirurgia - Complicacions ,medicine.diagnostic_test ,CK-MB, creatine kinase-myocardial band ,eNOS, endothelial nitric oxide synthase ,Iron deficiency ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Surgical Procedures, Operative::Surgical Procedures, Operative::Minimally Invasive Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Sgc, soluble guanylyl cyclase ,Cardiology ,cardiovascular system ,iNOS, inducible nitric oxide synthase ,Infart de miocardi - Imatgeria ,Cardiology and Cardiovascular Medicine ,STEMI, ST-segment elevation acute myocardial infarction ,soluble guanylate cyclase ,medicine.medical_specialty ,Ischemia ,acute myocardial infarction ,Acute myocardial infarction ,MVO, microvascular obstruction ,Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency [DISEASES] ,Myocardial reperfusion ,Enos, endothelial nitric oxide synthase ,Cardiac magnetic resonance imaging ,Clinical Research ,Internal medicine ,STIR, short tau inversion recovery ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,medicine ,Soluble guanylate cyclase ,HSP90, heat-shock protein 90 ,cardiovascular diseases ,Ventricular remodeling ,LV, left ventricular ,endothelial nitric oxide synthase ,Dèficit de ferro ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,Coronary occlusion ,Inos, inducible nitric oxide synthase ,PKG, protein kinase G ,Endothelial nitric oxide synthase ,business ,cGMP-dependent protein kinase ,VASP, vasodilator-stimulated phosphoprotein - Abstract
Visual Abstract, Highlights • In patients with STEMI treated with primary percutaneous coronary intervention, iron deficiency is associated with larger infarcts, more extensive microvascular obstruction, and a higher frequency of adverse left ventricular remodeling. • An iron-deficient diet reduces the tolerance to ischemia/reperfusion in mice at least in part by interfering with the cardioprotective pathway eNOS/soluble guanylate cyclase/protein kinase G. • An iron-deficient diet reduces eNOS activity by increasing oxidative/nitrosative stress and its proteasome-dependent degradation. • Not only iron excess but also iron deficiency may have deleterious effects in the context of acute myocardial ischemia., Summary In patients with a first anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention, iron deficiency (ID) was associated with larger infarcts, more extensive microvascular obstruction, and higher frequency of adverse left ventricular remodeling as assessed by cardiac magnetic resonance imaging. In mice, an ID diet reduced the activity of the endothelial nitric oxide synthase/soluble guanylate cyclase/protein kinase G pathway in association with oxidative/nitrosative stress and increased infarct size after transient coronary occlusion. Iron supplementation or administration of an sGC activator before ischemia prevented the effects of the ID diet in mice. Not only iron excess, but also ID, may have deleterious effects in the setting of ischemia and reperfusion.
- Published
- 2021
41. Optimal opportunistic screening of atrial fibrillation using pulse palpation in cardiology outpatient clinics: Who and how
- Author
-
Bañeras, Jordi, Pariggiano, Ivana, Ródenas-Alesina, Eduard, Oristrell, Gerard, Escalona, Roxana, Miranda, Berta, Rello, Pau, Soriano, Toni, Gordon, Blanca, Belahnech, Yassin, Calabrò, Paolo, García-Dorado, David, Ferreira-González, Ignacio, Radua, Joaquim, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Bañeras J, García-Dorado D] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER CV, ISCIII, Madrid, Spain. [Pariggiano I] Division of Clinical Cardiology, A.O.R.N. 'Sant’Anna e San Sebastiano', Caserta, Italy. Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy. [Ródenas-Alesina E, Oristrell G, Escalona R, Miranda B, Rello P, Soriano T, Gordon B, Belahnech Y] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER ESP, ISC-III, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, Bañeras, Jordi, Pariggiano, Ivana, Ródenas-Alesina, Eduard, Oristrell, Gerard, Escalona, Roxana, Miranda, Berta, Rello, Pau, Soriano, Toni, Gordon, Blanca, Belahnech, Yassin, Calabro', Paolo, García-Dorado, David, Ferreira-González, Ignacio, and Radua, Joaquim
- Subjects
Adult ,Heart Failure ,Palpation ,Multidisciplinary ,enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial [ENFERMEDADES] ,Otros calificadores::/diagnóstico [Otros calificadores] ,Cardiology ,Middle Aged ,Ambulatory Care Facilities ,Ambulatory Care Facilitie ,Electrocardiography ,Fibril·lació auricular - Diagnòstic ,Electrocardiografia ,diagnóstico::técnicas y procedimientos diagnósticos::técnicas diagnósticas cardiovasculares::pruebas de función cardíaca::electrocardiografía [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Atrial Fibrillation ,Other subheadings::/diagnosis [Other subheadings] ,Humans ,Mass Screening ,Pulse ,Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation [DISEASES] ,Human ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Cardiovascular::Heart Function Tests::Electrocardiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Aged - Abstract
Background Atrial fibrillation (AF) remain a prevalent undiagnosed condition frequently encountered in primary care. Objective We aimed to find the parameters that optimize the diagnostic accuracy of pulse palpation to detect AF. We also aimed to create a simple algorithm for selecting which individuals would benefit from pulse palpation and, if positive, receive an ECG to detect AF. Methods Nurses from four Cardiology outpatient clinics palpated 7,844 pulses according to a randomized list of arterial territories and durations of measure and immediately followed by a 12-lead ECG, which we used as the reference standard. We calculated the sensitivity and specificity of the palpation parameters. We also assessed whether diagnostic accuracy depended on the nurse’s experience or on a list of clinical factors of the patients. With this information, we estimated the positive predictive values and false omission rates according to very few clinical factors readily available in primary care (age, sex, and diagnosis of heart failure) and used them to create the algorithm. Results The parameters associated with the highest diagnostic accuracy were palpation of the radial artery and classifying as irregular those palpations in which the nurse was uncertain about pulse regularity or unable to palpate pulse (sensitivity = 79%; specificity = 86%). Specificity decreased with age. Neither the nurse’s experience nor any investigated clinical factor influenced diagnostic accuracy. We provide the algorithm to select the ≥40 years old individuals that would benefit from a pulse palpation screening: a) do nothing in Conclusions Opportunistic screening for AF using optimal pulse palpation in candidate individuals according to a simple algorithm may have high effectiveness in detecting AF in primary care.
- Published
- 2022
- Full Text
- View/download PDF
42. Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients
- Author
-
Alejandra Planas, Olga Simó-Servat, Cristina Hernández, Ángel Ortiz-Zúñiga, Joan Ramón Marsal, José R. Herance, Ignacio Ferreira-González, Rafael Simó, Institut Català de la Salut, [Planas A, Simó-Servat O, Hernández C, Ortiz-Zúñiga Á, Simó R] Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Marsal JR, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER en Epidemiología y Salud Pública (CIBERESP), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Hernández C] Grup de Recerca en Imatge Molecular Mèdica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBBIM-Nanomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Spanish Institute of Health (ISCIII), 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::angiopatías diabéticas::retinopatía diabética [ENFERMEDADES] ,Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Angiopathies::Diabetic Retinopathy [DISEASES] ,Cardiovascular Diseases [DISEASES] ,Otros calificadores::/diagnóstico [Otros calificadores] ,Medicine (miscellaneous) ,cardiovascular disease biomarkers ,Article ,aminoácidos, péptidos y proteínas::proteínas::productos finales de la degradación proteica::productos finales de la glicación avanzada [COMPUESTOS QUÍMICOS Y DROGAS] ,diabetic retinopathy ,cardiovascular disease ,advanced glycation end-products ,type 2 diabetes ,diabetic complications ,Amino Acids, Peptides, and Proteins::Proteins::Protein Degradation End Products::Glycation End Products, Advanced [CHEMICALS AND DRUGS] ,Retinopatia diabètica ,Other subheadings::/diagnosis [Other subheadings] ,Medicine ,Cor - Malalties - Factors de risc ,Glicosilació ,enfermedades cardiovasculares [ENFERMEDADES] - Abstract
Cardiovascular disease biomarkers; Diabetic complications; Type 2 diabetes Biomarcadores de enfermedades cardiovasculares; Complicaciones de la diabetes; Diabetes tipo 2 Biomarcadors de malalties cardiovasculars; Complicacions de la diabetis; Diabetis tipus 2 Risk of cardiovascular events is not homogeneous in subjects with type 2 diabetes; therefore, its early identification remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy and accumulation of advanced glycation end-products in subcutaneous tissue can help identify patients at high risk of cardiovascular events. For this purpose, we conducted a prospective study (mean follow-up: 4.35 years) comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls matched by age and sex. The primary outcome was defined as the composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. The Cox proportional hazard multiple regression analysis was used to determine the independent predictors of cardiovascular events. The patients with type 2 diabetes had significantly more cardiovascular events than the non-diabetic subjects. Apart from the classic factors such as age, sex and coronary artery calcium score, we observed that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue were independent predictors of cardiovascular events. We conclude that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue could be useful biomarkers for selecting type 2 diabetic patients in whom the screening for cardiovascular disease should be prioritized, thereby creating more personalized and cost-effective medicine. This research was funded by grants from the Spanish Institute of Health (ISCIII) in the setting of Integrative Excellence Projects (PIE 2013/27) and the European Foundation for the Study of Diabetes (EFSD Pilot Research Grant Programme for Innovative Measurement of Diabetes Outcomes 2017). The study funders were not involved in the design of the study.
- Published
- 2021
- Full Text
- View/download PDF
43. Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications
- Author
-
Matthias Schwenkglenks, Lars G. Hemkens, Ignacio Ferreira-González, Mihaela Stegert, Heike Raatz, Anette Blümle, Elie A. Akl, Theresa Bengough, Dirk Bassler, Dominik Mertz, Alonso Carrasco-Labra, John J. You, Sohail M. Mulla, Kelechi K Olu, Kari A.O. Tikkinen, Yuki Tomonaga, Gordon H. Guyatt, Martin A. Walter, Per Olav Vandvik, Viktoria Gloy, Ignacio Neumann, Bernard Burnand, Markus Faulhaber, Rachel Rosenthal, Stefan Schandelmaier, Alain J Nordmann, Benjamin Kasenda, Joerg J Meerpohl, Heiner C. Bucher, Lorenzo Moja, Erik von Elm, Matthias Briel, Shanil Ebrahim, Alain Amstutz, Jason W. Busse, Bradley C. Johnston, Francois Lamontagne, Ramon Saccilotto, Xin Sun, Urologian yksikkö, Clinicum, Hjelt Institute (-2014), Department of Public Health, DISCO Study Group, Kasenda, B., Schandelmaier, S., Sun, X., von Elm, E., You, J., Blümle, A., Tomonaga, Y., Saccilotto, R., Amstutz, A., Bengough, T., Meerpohl, JJ., Stegert, M., Olu, KK., Tikkinen, KA., Neumann, I., Carrasco-Labra, A., Faulhaber, M., Mulla, SM., Mertz, D., Akl, E., Bassler, D., Busse, JW., Ferreira-González, I., Lamontagne, F., Nordmann, A., Gloy, V., Raatz, H., Moja, L., Rosenthal, R., Ebrahim, S., Vandvik, PO., Johnston, BC., Walter, MA., Burnand, B., Schwenkglenks, M., Hemkens, LG., Bucher, HC., Guyatt, GH., and Briel, M.
- Subjects
Research design ,Canada ,Pediatrics ,medicine.medical_specialty ,education ,Trial protocol ,MEDLINE ,Alternative medicine ,610 Medicine & health ,Subgroup analysis ,Randomised controlled trials ,Corrections ,law.invention ,Cohort Studies ,Clinical Protocols ,Randomized controlled trial ,law ,Germany ,medicine ,Humans ,Randomized Controlled Trials as Topic ,Publishing ,Research ethics ,business.industry ,Research ,Data Collection ,General Medicine ,3142 Public health care science, environmental and occupational health ,3. Good health ,Data Collection/methods ,Publishing/statistics & numerical data ,Randomized Controlled Trials as Topic/methods ,Research Design ,Switzerland ,Family medicine ,Cohort ,trial protocols ,Physical therapy ,business ,Cohort study - Abstract
Correction: Volume: 349 Article Number: g4921 DOI: 10.1136/bmj.g4921 OBJECTIVE: To investigate the planning of subgroup analyses in protocols of randomised controlled trials and the agreement with corresponding full journal publications. DESIGN: Cohort of protocols of randomised controlled trial and subsequent full journal publications. SETTING: Six research ethics committees in Switzerland, Germany, and Canada. DATA SOURCES: 894 protocols of randomised controlled trial involving patients approved by participating research ethics committees between 2000 and 2003 and 515 subsequent full journal publications. RESULTS: Of 894 protocols of randomised controlled trials, 252 (28.2%) included one or more planned subgroup analyses. Of those, 17 (6.7%) provided a clear hypothesis for at least one subgroup analysis, 10 (4.0%) anticipated the direction of a subgroup effect, and 87 (34.5%) planned a statistical test for interaction. Industry sponsored trials more often planned subgroup analyses compared with investigator sponsored trials (195/551 (35.4%) v 57/343 (16.6%), P
- Published
- 2014
- Full Text
- View/download PDF
44. Risk of Stroke and Incident Atrial Fibrillation in Patients in Sinus Rhythm With Nonischemic Dilated Cardiomyopathy.
- Author
-
Ródenas-Alesina E, Lozano-Torres J, Tobías-Castillo PE, Badia-Molins C, Calvo-Barceló M, Vila-Olives R, Casas-Masnou G, San Emeterio AO, Soriano-Colomé T, Fernández-Galera R, Méndez-Fernández AB, Barrabés JA, Rodríguez-Palomares J, and Ferreira-González I
- Subjects
- Humans, Male, Female, Middle Aged, Risk Assessment methods, Aged, Incidence, Stroke epidemiology, Stroke etiology, Stroke Volume physiology, Risk Factors, Retrospective Studies, Heart Atria diagnostic imaging, Heart Atria physiopathology, Prognosis, Cardiomyopathy, Dilated physiopathology, Cardiomyopathy, Dilated complications, Cardiomyopathy, Dilated epidemiology, Atrial Fibrillation epidemiology, Atrial Fibrillation physiopathology, Atrial Fibrillation complications, Echocardiography
- Abstract
Nonischemic dilated cardiomyopathy (NIDCM) is associated with an increased risk of atrial fibrillation (AF) and stroke, especially in patients with high CHA
2 DS2 -VASc. We aimed to identify variables associated with incident AF or stroke using left atrial deformation analysis and its prognostic value added to CHA2 DS2 -VASc score. Patients with NIDCM and left ventricular ejection fraction <50% in sinus rhythm were included between January 2015 and December 2019. Left atrial volume index (LAVI) and atrial strain were used in combination with the CHA2 DS2 -VAS score to predict ischemic stroke or incident AF. Proportional hazards Cox regression was used to provide hazard ratios (HRs). There were 338 patients included. After a median follow-up of 3.6 years, the end point occurred in 41 patients (12.1%). LAVI outperformed other echocardiographic parameters, with a significant improvement in risk reclassification compared with CHA2 DS2 -VASc alone (net reclassification index 0.6, increase in Harrell's C from 0.63 to 0.73, p = 0.003), and remained significant after multivariate adjustment. LAVI was associated with both components of the end point separately. The best cutoff for LAVI was 44 ml/m2 . LAVI ≥44 ml/m2 increased the risk of the end point among those with CHA2 DS2 -VASc ≥3 (HR 6.0, 95% confidence interval 2.6 to 13.5) but not in those with CHA2 DS2 -VASc <3 (HR 1.2, 95% confidence interval 0.3 to 4.5). Competing risk analysis did not alter the results. In conclusion, LAVI might be used to assess the risk of incident AF or stroke in NIDCM. Patients with LAVI ≥44 ml/m2 and CHA2 DS2 -VASc ≥3 could be at high risk of AF and stroke and may benefit from more intensive surveillance., Competing Interests: Declaration of competing interest The authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
45. Prediction of Major Adverse Coronary Events Using the Coronary Risk Score in Women.
- Author
-
Romero-Farina G, Aguadé-Bruix S, and Ferreira-González I
- Subjects
- Humans, Female, Aged, Retrospective Studies, Risk Assessment, Tomography, Emission-Computed, Single-Photon, Middle Aged, Predictive Value of Tests, Risk Factors, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease epidemiology, Myocardial Perfusion Imaging
- Abstract
Purpose To establish a COronary Risk Score in WOmen (CORSWO) to predict major adverse coronary events (MACE). Materials and Methods This retrospective analysis included 2226 female individuals (mean age, 66.7 years ± 11.6 [SD]) from a cohort of 25 943 consecutive patients referred for clinical gated SPECT myocardial perfusion imaging (gSPECT MPI). During the follow-up (mean, 4 years ± 2.7) after gSPECT MPI, occurrence of MACE (unstable angina requiring hospitalization, nonfatal myocardial infarction, coronary revascularization, cardiac death) was assessed. The patients were divided into training ( n = 1460) and validation ( n = 766) groups. To obtain the predictor model, multiple Cox regression analyses were performed. Results In the training group, 148 female individuals had MACE (2.6% per year). The best model (area under the receiver operating characteristic curve [AUC]: 0.80 [95% CI: 0.74, 0.83]; Brier score: 0.08) to predict MACE in female individuals included the following variables: age older than 69 years (hazard ratio [HR]: 1.58, P = .01), diabetes mellitus (HR: 1.47, P = .03), pharmacologic test (HR: 1.63, P = .01), ST-segment depression (≥1 mm) (HR: 2.02, P < .001), myocardial ischemia greater than 5% (HR: 2.21, P < .001), perfusion defect at rest greater than 9% (HR: 1.96, P = .009), perfusion defect at stress greater than 6% (HR: 1.63, P = .03), and end-systolic volume index greater than 15 mL (HR: 2.04, P < .001). During validation, the model achieved moderate performance (AUC: 0.78 [95% CI: 0.70, 0.83]). CORSWO obtained from these variables allowed for stratification of female individuals into four risk levels: low (score: 0-3, HR: 1), moderate (score: 4-6, HR: 1.58), high (score: 7-11, HR: 4.13), and very high (score: >11, HR: 13.87). The high and very high risk levels (HR: 5.29) predicted MACE in female individuals, with excellent performance (AUC: 0.78 [95% CI: 0.72, 0.80]). Conclusion With clinical, stress test, and gSPECT MPI variables, CORSWO effectively stratified female individuals according to coronary risk and was able to detect those with high and very high risk. Keywords: SPECT, Cardiac, Coronary Arteries, Women, Risk Stratification, Cardiac Event, CORSWO, MACE, Gated SPECT Supplemental material is available for this article. ©RSNA, 2024.
- Published
- 2024
- Full Text
- View/download PDF
46. Cardiac resynchronization therapy with triple fusion using the SyncAV dynamic algorithm compared to conventionally optimized biventricular pacing: Results from the multicentric, randomized, double-blinded CRUSTY trial.
- Author
-
Francisco-Pascual J, Adeliño R, Quesada A, Sainz Godoy I, Exposito V, Ferrando J, Fernadez Armenta J, Cabanas P, Pérez-Rodon J, Santos-Ortega A, Villuendas R, Trucco E, Benito B, Jordan-Marchite P, Rodríguez-Palomares JF, Ferreira-González I, and Rivas-Gándara N
- Published
- 2024
- Full Text
- View/download PDF
47. Left atrial strain in non-ischemic dilated cardiomyopathy in sinus rhythm: Prognostic implications and interrelationship with left ventricular deformation.
- Author
-
Ródenas-Alesina E, Lozano-Torres J, Badia-Molins C, Tobías-Castillo PE, Vila-Olives R, Calvo-Barceló M, Casas-Masnou G, Soriano-Colomé T, Emeterio AOS, Fernández-Galera R, Méndez-Fernández AB, Barrabés JA, Ferreira-González I, and Rodríguez-Palomares J
- Abstract
Background: Left atrial deformation analysis may identify patients at higher risk of adverse events in the setting of non-ischemic dilated cardiomyopathy (NIDCM). The purpose was to determine the association between peak longitudinal (PALS) and contraction (PACS) LA strain in NIDCM, accounting for left ventricular global longitudinal strain (LV-GLS)., Methods: Consecutive patients with NIDCM, sinus rhythm and LV ejection fraction (LVEF)<50 % were included. PALS, PACS and LV-GLS were obtained from echocardiography images. The composite outcome was a combination of hospitalization for heart failure, cardiovascular death, or ventricular arrhythmia. The association with the composite outcome was assessed using Cox regression and a classification and regression tree (CART) analysis was performed., Results: Among 347 patients included (median age 66 years old, median LVEF 35 %), median PALS and PACS values of 16 % and 9 %. After a median follow-up of 3.6 years, the composite outcome occurred in 70 (20.2 %) patients. PACS ≤8 % was associated with the composite outcome (adjusted HR = 2.73, 95 %CI 1.33-5.60), mostly by increasing the risk of heart failure admission. LV-GLS increased the risk of the composite outcome among patients with PACS>8 % (HR = 1.20, 95 %CI 1.07-1.35). PALS more strongly correlated with LV-GLS (Spearmans' rho = -0.71) than PACS (rho = -0.5). A decreased PALS/LV-GLS ratio was associated with higher rates of the composite outcome., Conclusion: LA dysfunction is a major determinant of the composite outcome in NIDCM with LVEF <50 % and should be routinely assessed. PACS may perform better than PALS when combined with LV-GLS, probably due to lesser dependency from mitral annular motion., Competing Interests: Declaration of competing interest None declared related to this study., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
48. Present and future of aortic risk assessment in patients with heritable thoracic aortic diseases.
- Author
-
Teixido-Tura G, Dux-Santoy L, Badia C, Limeres J, Guala A, Evangelista Masip A, Ferreira-González I, and Rodríguez-Palomares J
- Abstract
Heritable thoracic aortic diseases (HTAD) are a group of diverse genetic conditions characterized by an increased risk of aortic complications. The standard surveillance of these patients involves monitoring aortic diameters until a defined threshold is reached, at which point preventive aortic surgery is recommended. However, assessing aortic risk in these patients is far more complex and, in many aspects, remains incompletely understood. Several factors contribute to this complexity, including the diversity and low prevalence of the conditions within HTAD and the limited understanding of the factors influencing the progression of aortic dilation and the advent of acute aortic events. This article reviews current knowledge on clinical, genetic, and imaging factors related to aortic risk in HTAD and explores their potential future roles in improving risk assessment. By advancing our understanding of these factors, we aim to enhance the precision of risk stratification and develop more effective, personalized management strategies for HTAD patients, with the final goal of improving clinical outcomes and quality of life in individuals affected by these genetic disorders., Competing Interests: CONFLICTS OF INTEREST All authors declare that they do not have any conflicts of interest, (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Impact of thoracic endovascular aortic repair following blunt traumatic thoracic aortic injury on blood pressure.
- Author
-
Guala A, Gil-Sala D, Garcia Reyes ME, Azancot MA, Dux-Santoy L, Allegue Allegue N, Teixido-Turà G, Goncalves Martins G, Galian-Gay L, Garrido-Oliver J, Constenla García I, Evangelista A, Tello Díaz C, Carrasco-Poves A, Morales-Galán A, Ferreira-González I, Rodríguez-Palomares J, and Bellmunt Montoya S
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Vascular System Injuries surgery, Vascular System Injuries physiopathology, Vascular System Injuries diagnosis, Vascular System Injuries diagnostic imaging, Blood Pressure, Thoracic Injuries surgery, Thoracic Injuries physiopathology, Blood Vessel Prosthesis Implantation adverse effects, Treatment Outcome, Risk Factors, Time Factors, Vascular Stiffness, Prevalence, Endovascular Aneurysm Repair, Aorta, Thoracic surgery, Aorta, Thoracic physiopathology, Aorta, Thoracic diagnostic imaging, Aorta, Thoracic injuries, Wounds, Nonpenetrating surgery, Wounds, Nonpenetrating physiopathology, Wounds, Nonpenetrating diagnostic imaging, Endovascular Procedures methods, Endovascular Procedures adverse effects, Hypertension physiopathology
- Abstract
Background: Blunt traumatic thoracic aortic injuries (BTAIs) are associated with a high mortality rate. Thoracic endovascular aortic repair (TEVAR) is the most frequently used surgical strategy in patients with BTAI, as it offers good short- and middle-term results. Previous studies have reported an abnormally high prevalence of hypertension (HT) in these patients. This work aimed to describe the long-term prevalence of HT and provide a comprehensive evaluation of the biomechanical, clinical, and functional factors involved in HT development., Methods: Twenty-six patients treated with TEVAR following BTAI with no history of HT at the time of trauma were enrolled. They were matched with 37 healthy volunteers based on age, sex, and body surface area and underwent a comprehensive follow-up study, including cardiovascular magnetic resonance, 24-hour ambulatory blood pressure monitoring, and assessment of carotid-femoral pulse wave velocity (cfPWV, a measure of aortic stiffness) and flow-mediated vasodilation., Results: The mean patient age was 43.5 ± 12.9 years, and the majority were male (23 of 26; 88.5%). At a mean of 120.2 ± 69.7 months after intervention, 17 patients (65%) presented with HT, 14 (54%) had abnormal nighttime blood pressure dipping, and 6 (23%) high cfPWV. New-onset HT was related to a more proximal TEVAR landing zone and greater distal oversizing. Abnormal nighttime blood pressure was related to high cfPWV, which in turn was associated with TEVAR length and premature arterial aging., Conclusions: HT frequently occurs otherwise healthy subjects undergoing TEVAR implantation after BTAI. TEVAR stiffness and length, the proximal landing zone, and distal oversizing are potentially modifiable surgical characteristics related to abnormal blood pressure., (Copyright © 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Ethics in clinical research: what you should know before starting a study.
- Author
-
Pérez de Prado A, Castro Conde A, and Ferreira-González I
- Subjects
- Humans, Informed Consent ethics, Biomedical Research ethics
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.